Literature DB >> 20592029

Peroxisome proliferator-activated receptor {delta} activators induce IL-8 expression in nonstimulated endothelial cells in a transcriptional and posttranscriptional manner.

Markus Meissner1, Igor Hrgovic, Monika Doll, Julia Naidenow, Gabi Reichenbach, Tsige Hailemariam-Jahn, Despina Michailidou, Jens Gille, Roland Kaufmann.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that are implicated in the regulation of lipid and glucose homeostasis. PPAR agonists have been shown to control inflammatory processes, in part by inhibiting distinct proinflammatory genes (e.g. Il-1β and IFN-γ). IL-8 is a member of the proinflammatory chemokine family that is important for various functions, such as mediating the adhesion of eosinophilic granulocytes onto endothelial cells. The influence of PPARδ activators on the expression of IL-8 in noninduced quiescent endothelial cells is unclear. Therefore, we explored the influence of PPARδ activators on the expression of IL-8 in nonstimulated endothelial cells. PPARδ agonists induce IL-8 expression in human umbilical vein endothelial cells. This induction is demonstrated at the level of both protein and mRNA expression. Transcriptional activation studies using IL-8 reporter gene constructs and DNA binding assays revealed that PPARδ agonists mediated their effects via an NFκB binding site. It is well known that IL-8 is also regulated by mRNA stability. To provide further evidence for this concept, we performed mRNA stability assays and found that PPARδ agonists induce the mRNA stability of IL-8. In addition, we showed that PPARδ agonists induce the phosphorylation of ERK1/2 and p38, which are known to be involved in the increase of mRNA stability. The inhibition of these MAPK signaling pathways resulted in a significant suppression of the induced IL-8 expression and the reduced mRNA stability. Therefore, our data provide the first evidence that PPARδ induces IL-8 expression in nonstimulated endothelial cells via transcriptional as well as posttranscriptional mechanisms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20592029      PMCID: PMC2962479          DOI: 10.1074/jbc.M110.137943

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  IL-17A acts via p38 MAPK to increase stability of TNF-alpha-induced IL-8 mRNA in human ASM.

Authors:  Sheridan Henness; Eveline van Thoor; Qi Ge; Carol L Armour; J Margaret Hughes; Alaina J Ammit
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-06       Impact factor: 5.464

2.  PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells.

Authors:  Yves Rival; Nathalie Benéteau; Thierry Taillandier; Mylène Pezet; Elisabeth Dupont-Passelaigue; Jean François Patoiseau; Didier Junquéro; Francis C Colpaert; André Delhon
Journal:  Eur J Pharmacol       Date:  2002-01-25       Impact factor: 4.432

3.  Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis.

Authors:  Aihua Li; Michelle L Varney; Jason Valasek; Maurice Godfrey; Bhavana J Dave; Rakesh K Singh
Journal:  Angiogenesis       Date:  2005       Impact factor: 9.596

Review 4.  Multiple control of interleukin-8 gene expression.

Authors:  Elke Hoffmann; Oliver Dittrich-Breiholz; Helmut Holtmann; Michael Kracht
Journal:  J Leukoc Biol       Date:  2002-11       Impact factor: 4.962

5.  Activation of ERK2 by respiratory syncytial virus in A549 cells is linked to the production of interleukin 8.

Authors:  W Chen; M M Monick; A B Carter; G W Hunninghake
Journal:  Exp Lung Res       Date:  2000 Jan-Feb       Impact factor: 2.459

6.  Magnesium sulfate suppresses inflammatory responses by human umbilical vein endothelial cells (HuVECs) through the NFkappaB pathway.

Authors:  Burton Rochelson; Oonagh Dowling; Nadav Schwartz; Christine N Metz
Journal:  J Reprod Immunol       Date:  2006-09-06       Impact factor: 4.054

7.  Effect of ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in human lung cancer cell lines.

Authors:  Pengfei He; Michael G Borland; Bokai Zhu; Arun K Sharma; Shantu Amin; Karam El-Bayoumy; Frank J Gonzalez; Jeffrey M Peters
Journal:  Toxicology       Date:  2008-10-02       Impact factor: 4.221

8.  Comparison of PPARδ and PPARγ in inhibiting the pro-inflammatory effects of C-reactive protein in endothelial cells.

Authors:  Yao-Jen Liang; Yuan-Chun Liu; Chao-Yi Chen; Ling-Ping Lai; Kou-Gi Shyu; Shiow-Jen Juang; Bao-Wei Wang; Jyh Gang Leu
Journal:  Int J Cardiol       Date:  2009-04-22       Impact factor: 4.164

Review 9.  PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.

Authors:  Barbara Gross; Bart Staels
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2007-12       Impact factor: 4.690

10.  Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) inhibits chemically induced skin tumorigenesis.

Authors:  Moses T Bility; Meghann K Devlin-Durante; Nicholas Blazanin; Adam B Glick; Jerrold M Ward; Boo Hyon Kang; Mary J Kennett; Frank J Gonzalez; Jeffrey M Peters
Journal:  Carcinogenesis       Date:  2008-09-17       Impact factor: 4.741

View more
  8 in total

1.  Metastasis regulation by PPARD expression in cancer cells.

Authors:  Xiangsheng Zuo; Weiguo Xu; Min Xu; Rui Tian; Micheline J Moussalli; Fei Mao; Xiaofeng Zheng; Jing Wang; Jeffrey S Morris; Mihai Gagea; Cathy Eng; Scott Kopetz; Dipen M Maru; Asif Rashid; Russell Broaddus; Daoyan Wei; Mien-Chie Hung; Anil K Sood; Imad Shureiqi
Journal:  JCI Insight       Date:  2017-01-12

Review 2.  Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer.

Authors:  Nicole Wagner; Kay-Dietrich Wagner
Journal:  Cells       Date:  2022-08-05       Impact factor: 7.666

Review 3.  PPARs and Tumor Microenvironment: The Emerging Roles of the Metabolic Master Regulators in Tumor Stromal-Epithelial Crosstalk and Carcinogenesis.

Authors:  Hong Sheng Cheng; Yun Sheng Yip; Eldeen Kai Yi Lim; Walter Wahli; Nguan Soon Tan
Journal:  Cancers (Basel)       Date:  2021-04-29       Impact factor: 6.639

4.  Role of an indole-thiazolidine molecule PPAR pan-agonist and COX inhibitor on inflammation and microcirculatory damage in acute gastric lesions.

Authors:  José Roberto Santin; Isabel Daufenback Machado; Stephen F P Rodrigues; Simone Teixeira; Marcelo N Muscará; Suely Lins Galdino; Ivan da Rocha Pitta; Sandra H P Farsky
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

5.  Mxi1-0 regulates the growth of human umbilical vein endothelial cells through extracellular signal-regulated kinase 1/2 (ERK1/2) and interleukin-8 (IL-8)-dependent pathways.

Authors:  Weiling Wu; Zhenzhen Hu; Feng Wang; Hao Gu; Xiuqin Jiang; Jinjin Xu; Xi Zhan; Datong Zheng; Zhengdong Zhang
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

6.  Urotensin II induces interleukin 8 expression in human umbilical vein endothelial cells.

Authors:  Chung-Yi Lee; Yi-Tin Tsai; Shih-Hurng Loh; Ju-Chi Liu; Tso-Hsiao Chen; Hung-Hsing Chao; Tzu-Hurng Cheng; Jin-Jer Chen
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

7.  Peroxisome proliferator-activated receptor (PPAR) α and δ activators induce ICAM-1 expression in quiescent non stimulated endothelial cells.

Authors:  Julia Naidenow; Igor Hrgovic; Monika Doll; Tsige Hailemariam-Jahn; Victoria Lang; Johannes Kleemann; Stefan Kippenberger; Roland Kaufmann; Nadja Zöller; Markus Meissner
Journal:  J Inflamm (Lond)       Date:  2016-08-20       Impact factor: 4.981

Review 8.  PPAR Beta/Delta and the Hallmarks of Cancer.

Authors:  Nicole Wagner; Kay-Dietrich Wagner
Journal:  Cells       Date:  2020-05-04       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.